Comparison

Delvant vs GlobalData

Both produce clinical and pharma intelligence. They sit in different positions of the same market. This page is for buyers deciding whether to subscribe to syndicated reports or commission a bounded custom deliverable.

Last updated 2026-05-15. Snapshot based on public information; refreshed quarterly.

What each one is

GlobalData is a syndicated data platform. It maintains licensed databases (pipeline, deals, epidemiology, forecasting) covering thousands of drugs across many therapeutic areas, and publishes pre-scoped reports that buyers can purchase off-the-shelf. Reports are written to a templated framework so they remain comparable across assets. Public list prices for syndicated reports sit around USD 3,495 per report; database subscriptions are quoted separately.

Delvant is a bounded custom-intelligence service. Each engagement starts from one or two specific questions a buyer cannot answer with a templated report, scopes the comparator set, runs a fresh search against locked anchor sources (ClinicalTrials.gov, EMA, FDA, PubMed, EHA, ASH, EULAR, AACR, ASCO, ESMO), tags every claim by provenance tier (Sourced, Inferred, Opinion, Hedged), and ships a 10-30 page deliverable in 5-15 business days. Tier 1 briefs start at EUR 3,500. Tier 2 strategic dossiers run EUR 12,000-35,000.

Side-by-side

Dimension GlobalData Delvant
Product shape Syndicated reports + database subscriptions. Pre-scoped to fit a templated framework. Custom-scoped deliverable. One-to-three commissioned questions per engagement.
Therapeutic area scope Broad. Covers most major oncology, cardiovascular, neurology, autoimmune, rare-disease, infectious-disease areas. Narrow. Core: rare hematology, immune cytopenias (ITP, AIHA, HDFN), plasma-derived therapeutics. Adjacent: rare oncology, IgG autoimmune, transplant.
Methodology transparency High-level methodology notes per report. Per-claim source mapping not exposed. Per-claim tier tags (Sourced / Inferred / Opinion / Hedged) visible inline. Methodology section + audit trail in every deliverable.
Citation discipline References listed; mapping of individual claims to source not disclosed by default. Every Sourced claim re-verified at the cited URL during Gate A pass. Page-locked references.
Turnaround Immediate for in-library reports. Custom syndicated work runs to a publication calendar. 5 business days (T1). 10-15 business days (T2). Fixed schedule, no rush-fee compression.
Indicative price (public) Approx. USD 3,495 per syndicated report (single user); database subscriptions quoted separately. From EUR 3,500 (T1, 1 question, 10-15 pages). EUR 12,000-35,000 (T2, 2-3 questions, 20-30 pages).
Custom framing Limited. Off-the-shelf scope; bespoke work available through Custom Research at separate quote. Default. Scope defined at C1 (Day 1-2 frame check). Mid-draft framing review at C2.
Update model Rolling database updates; report refresh on platform cadence. Snapshot-dated per engagement. Staleness banner mandatory after 90 days. T3 quarterly retainer available from Q4 2026 for rolling reads.
AI methodology Disclosed at platform level; per-report AI use varies. AI-assisted retrieval and synthesis under documented human oversight; Gate A re-verifies every Sourced claim, Gate B runs LLM-council adversarial review. EU AI Act Article 4 deployer posture disclosed.
Buyer fit Strategy + commercial teams needing broad market coverage across many assets and geographies. Medical affairs, BD search-and-evaluation, small-biotech CMOs, life-sciences analysts who need a single sharp comparator answer with audit-grade citation.

When to pick which

GlobalData is a better fit when

  • You need broad coverage across many TAs and many assets at once.
  • You need an in-house database your strategy team can pivot inside daily.
  • The question fits a templated framework (e.g. global pipeline counts, drug deals tracker).
  • You already have internal analysts who can interpret syndicated outputs.
  • Speed beats custom framing; you want something on your desk today.

Delvant is a better fit when

  • You have one or two precise comparator questions a syndicated report does not answer cleanly.
  • You need every claim tier-tagged and citation-verified before sharing internally.
  • Your TA is in our core: rare hematology, immune cytopenias, plasma-derived, adjacent rare oncology and IgG autoimmune.
  • You will defend the conclusion in front of a medical or BD committee and need methodology transparency.
  • You can wait 5-15 business days for a bounded, signed-off deliverable.

Where Delvant deliberately does not compete

Delvant is not a database. There is no log-in, no live pipeline tracker, no daily deal feed. If your team needs to query thousands of assets every week, a syndicated platform like GlobalData (or Citeline, Evaluate, Clarivate Cortellis) is the right shape of tool.

Delvant is also not a multi-month strategy consultancy. If your question requires 8-12 weeks of senior advisory time, six interviews per geography, and a EUR 200K+ engagement, you should commission Putnam, Trinity, L.E.K., Health Advances, or ZS. Delvant covers the gap between those two: bounded custom work at 5-15 business day turnaround, EUR 3,500-35,000, narrow TA, audit-grade citation.

Honest note on pricing. The headline number on a single GlobalData report (around USD 3,495) sits inside Delvant's T1 band (from EUR 3,500). At that level the comparison is not about price - it is about whether the question you have is already in a syndicated catalogue, or whether it needs to be scoped from scratch. If the question fits a template, the syndicated report is faster and cheaper. If it does not fit a template, Delvant is built to answer it without paying multi-month consultancy rates.

Other comparisons

Side-by-side fit-call pages for adjacent providers.

Delvant vs Citeline: enterprise syndicated pharma stack vs commissioned engagement.

Delvant vs IQVIA Consulting: multi-month strategy consulting vs 5-15 day commissioned single-question deliverable.

Delvant vs Putnam Associates: senior-led boutique consultancy vs bounded custom deliverable.

Delvant vs Lucid Bio: bespoke biotech intelligence vs bounded custom clinical intelligence.

Not sure which fits your question?

30-minute scoping call. We will tell you whether a syndicated report answers it, whether a Delvant T1 or T2 fits, or whether you should be talking to a consultancy. Honest fit calls only.

Book a scoping call See engagement tiers